RESUMO
These data indicate that patients with nephrotic syndrome have diminished thyroid hormone binding proteins as shown by the result that 14 of the 22 nephrotic patients have low residual or reserve binding proteins as reflected by a low T3-I13 binding capacity. Of these 14 patients with low or reduced thyroid hormone binding proteins, only 5 have actually low PBI values while the rest have normal PBI except for 2 patients with unexplained high PBI levelsWhen correlated with their serum albumin all 14 patients with diminished T3-I13 binding capacity have severe hypoalbuminemia. This confirms the observation of Musa et al that in patients with nephrotid syndrome, the serum protein binding of thyroid hormone is more closely related to the serum albumin.(Conclusion)
RESUMO
An open, randomized multi-center trial, involving 700 infants, was conducted in order to compare a new measles mumps rubella (MMR) vaccine, SB MMR (containing a Jeryl Lynn derived mumps strain RIT 4385) with a widely used vaccine, Merck MMR, when given to children between 12-24 months. Infants were divided between 2 groups; group 1 received SB MMR while group 2 received Merck MMR. Solicited local and general symptoms were recorded using diary cards and antibody levels were measured using ELISA assays. There was a significantly lower incidence of redness (p < 0.001) and swelling (p = 0.03) observed in group 1 compared with group 2. The incidence of all other solicited local and general symptoms were comparable between groups. In initially seronegative subjects equivalent seroconversion rates and post-vaccination GMTs were observed between groups. In conclusion, these results demonstrate that SB MMR is safe and well tolerated when given to children at this age range, and has an equivalent immunogenic profile compared to the widely used Merck MMR vaccine.